Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hui Sheng semaglutide versus Wegovy in non-diabetic adults with obesity
ChiCTR2400094251Phase 3Completed
- Sponsor
- Peking University People's Hospital
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of semaglutide in obesity (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Percentage change in body weight from baseline to week 44. Started Dec 2024; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on ChiCTR2400094251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094251.